Unfortunately, there have not been conclusive studies performed in humans to date demonstrating that treatment with SGLT2 inhibitors in T2D leads to an increase in cardiac ketone oxidation rates, due, in part, to lack of characterized tracers that can be used to assess flux through ketone oxidation with either PET imaging or 13C MRS. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.